Clinical trials: open to volunteers, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Multiple Myeloma
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07569757
- Testing
- TQB2934 injection, Pomalidomide Capsule, Selinexor tablets
- Where
- 49 sites in China
- Volunteers
- 260 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alveolar Soft Part Sarcoma
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or…
- Trial name
- NCT07548177
- Testing
- Benmelstobart injection combined with Anlotinib hydrochloride capsule
- Where
- 15 sites in China
- Volunteers
- 33 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Cancer
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study.
- Trial name
- NCT07482592
- Testing
- TQB3205 capsules
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function
- Trial name
- NCT07538973
- Testing
- Anecatibin Fumarate Capsules
- Where
- 3 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the…
- Trial name
- NCT07480824
- Testing
- TQ05105
- Where
- 2 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Pancreatic Cancer
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid…
- Trial name
- NCT06821503
- Testing
- LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound)
- Where
- 16 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diffuse Large B Cell Lymphoma
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR…
- Trial name
- NCT06829771
- Testing
- TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx
- Where
- 25 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
- Trial name
- NCT07269145
- Testing
- TQB3122 Capsules
- Where
- 5 sites in China
- Volunteers
- 86 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hyperglycemia
A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects
TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Trial name
- NCT07327281
- Testing
- TQF3250 capsule
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Thyroid Cancer
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong…
- Trial name
- NCT06860971
- Testing
- AL2846 Capsules
- Where
- 35 sites in China
- Volunteers
- 144 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
- Trial name
- NCT07291050
- Testing
- TQB3217Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.
- Trial name
- NCT06122831
- Testing
- TQ05105 Tablets, TQB3617 Capsules
- Where
- 22 sites in China
- Volunteers
- 92 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can…
- Trial name
- NCT06682169
- Testing
- Rovadicitinib, Imatinib, Methotrexate
- Where
- 41 sites in China
- Volunteers
- 182 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
Clinical Trial of TQB3002 in Patients With Advanced Cancers
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
- Trial name
- NCT06662760
- Testing
- TQB3002 Tablets
- Where
- 11 sites in China
- Volunteers
- 150 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker.
- Trial name
- NCT07172126
- Testing
- TQB3201 tablets
- Where
- 3 sites in China
- Volunteers
- 291 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT07147946
- Testing
- TQC3721 Suspension for inhalation
- Where
- 76 sites in China
- Volunteers
- 666 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Primary Immune Thrombocytopenia
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
This study is an extension of the TQB3473-III-01 study, aimed at evaluating the safety and efficacy of TQB3473 tablets in adult patients with persistent or chronic ITP who have received at least one ITP standard treatment that is…
- Trial name
- NCT07083739
- Testing
- TQB3473 Tablets
- Where
- 51 sites in China
- Volunteers
- 320 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myeloid Malignancy
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.
- Trial name
- NCT07011186
- Testing
- TQB3909 Tablets + Azacitidine
- Where
- 21 sites in China
- Volunteers
- 138 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Primary Immune Thrombocytopenia
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP…
- Trial name
- NCT06900920
- Testing
- TQB3473 Tablets
- Where
- 53 sites in China
- Volunteers
- 199 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.